Over the last decade, there has been a dramatic rise in the use of cell-based assays for drug discovery as researchers work to bridge the gap between results from classical biochemical assays and clinical studies. The complexity of cell-based assays has also increased significantly. Traditionally, these experiments were based on monocultures of immortal cell lines, grown either in suspension or as two-dimensional adherent cultures, and they examined a single parameter per test. Developments in assay technologies now allow researchers to assess multiple parameters in parallel, enabling more reliable phenotype-based screening for identifying potential “hits” from large libraries of candidate compounds. The iQue3 Advanced flow cytometry platform supports these efforts.
Download this white paper from Sartorius to learn
The Scientist c/o LabX Media Group
1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801
Toll Free: 888.788.0328 | Phone: 705.528.6888
Email: privacy@the-scientist.com
© 1986-2022 The Scientist
The Scientist needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.